Palvella Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| PVLA | TARS | 0RC6.IL | LKFT | CGEM | 688177.SS | |
|---|---|---|---|---|---|---|
| Market cap | 2.34B | 3.23B | 1.22B | 2.25B | 767.61M | 7.38B |
| P/E (TTM) | — | — | 60.6 | 3.2 | — | — |
| Forward P/E | -20.5 | -138.1 | — | -28.6 | -5.1 | -26.2 |
| Price/book | 10.8 | 32.7 | 5.7 | 12.2 | 2.5 | 171.3 |
| Dividend yield | — | — | 2.09% | — | — | — |
| 1-year change | +101.89% | +1.44% | −8.11% | +9.26% | +69.93% | −34.43% |
| Today | +6.11% | −4.91% | +1.51% | +6.03% | −20.70% | +2.95% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All PVLA news ›Palvella Therapeutics (PVLA) Set to Release Earnings on Thursday
Posted by Danessa Lincoln on Nov 3rd, 2026 Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share for the quarter, missing…
Palvella Therapeutics to Participate in the Stifel 2026 Healthcare Conference
Rising Dragon Acquisition Corp. and HZJL Cayman Limited Announce Mutual Termination of Merger Agreement Shopify Sustains Rapid Growth with Revenue Up 32% and Free Cash Flow Margin of 22% Hydrofarm Eliminates $109 Million in Debt, Becoming…
Palvella Wins Priority FDA Review for Rare Disease Drug
WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) has secured priority review from the U.S. Food and Drug Administration for its experimental treatment of microcystic lymphatic malformations, putting the Wayne-based biotechnology…
Palvella Therapeutics gains FDA priority review with February decision target
QTORIN rapamycin could become the first approved treatment for microcystic lymphatic malformations, with a potential U.S. launch in early 2027. A potential first FDA-approved treatment for microcystic lymphatic malformations has a Feb. 28,…
Palvella Gets FDA Priority Review For QTORIN Rapamycin; Decision Expected In February 2027; Stock Up
Palvella Therapeutics Inc. (PVLA) announced that the U.S. FDA has accepted its NDA for QTORIN 3.9% rapamycin anhydrous gel and granted it Priority Review for treating microcystic lymphatic malformations (LMs). The FDA has set a target…
Palvella jumps as lead asset gets FDA priority review
Palvella Therapeutics (PVLA) stock rose after the company won the FDA priority review for its marketing application for its lead asset, Qtorin rapamycin. Read more here. - Palvella Therapeutics (PVLA) traded higher on Wednesday after the…
Palvella Therapeutics Eyes QTORIN Launch as Rare-Disease Pipeline Expands
Posted by Danessa Lincoln on Oct 28th, 2026 Palvella Therapeutics (NASDAQ:PVLA) is preparing for a potential commercial launch of QTORIN rapamycin while advancing additional rare skin and vascular anomaly programs, Chief Financial Officer…
Palvella to Discuss Drug Pipeline at October 20 Conference
WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) will participate in the Chardan 10th Annual Healthcare Conference on October 20, giving investors an opportunity to hear from management as the Wayne-based biotechnology company…
Palvella Therapeutics (NASDAQ:PVLA) Director Sells $935,202.64 in Stock
Posted by Danessa Lincoln on Oct 15th, 2026 NASDAQ PVLA traded down $5.93 during trading on Wednesday, hitting $122.58. 382,261 shares of the company’s stock traded hands, compared to its average volume of 237,043. The stock has a fifty…
Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026
Comprehensive Real-World Claims Analysis Identifies an Estimated 154,986 Patients Diagnosed With DSAP in the U.S. SELVA Maximal-Use Pharmacokinetic Substudy Demonstrates Low and Stable Systemic Rapamycin Exposure Over 24 Hours In August…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com5
- themarketsdaily.com3
- mugglehead.com1
- mychesco.com1
- rttnews.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 13 articles, not a forecast.